1. Home
  2. Medical News
  3. Allergy, Asthma, and Immunology
advertisement

Pharvaris Presents Phase 3 CHAPTER-3 Data for Oral Deucrictibant in Hereditary Angioedema Prevention at ACAAI 2026

Pharvaris Presents
11/13/2026

Key Takeaways

  • Pharvaris presented late-breaking Phase 3 CHAPTER-3 results at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix. Once-daily oral deucrictibant extended-release (XR) 40 mg cut the monthly HAE attack rate by 83% versus placebo over 24 weeks.
  • The company also presented final long-term Phase 2 prophylaxis data, Phase 3 on-demand analyses, modeling that supports using the two formulations together, an integrated cardiovascular safety review, and a U.S. claims analysis of HAE costs.
  • The results come from a company press release, and deucrictibant is investigational. The 87% reduction in HAE Type 1 or 2 is from a post hoc analysis, and the company’s comparison with injectable therapies isn’t from a head-to-head trial.

Pharvaris, a Swiss-based company developing oral bradykinin B2 receptor antagonists, summarized its oral and poster presentations at ACAAI 2026. Deucrictibant is being developed in two oral formulations: an extended-release tablet for prophylaxis and an immediate-release capsule for on-demand treatment of attacks. Hereditary angioedema is a rare disease marked by unpredictable swelling attacks driven by bradykinin.

The headline presentation was a late-breaking oral session on Saturday, November 14, delivered by Marc A. Riedl, M.D., of the Phase 3 CHAPTER-3 study (NCT06669754). It randomized 85 people with HAE, including HAE with normal C1 inhibitor, 2:1 to once-daily deucrictibant XR 40 mg or placebo for 24 weeks. The attack rate was 83% lower with deucrictibant than with placebo across all HAE types (p<0.0001), and 87% lower in a post hoc analysis of participants with HAE Type 1 or 2. The company says reductions appeared within the first week and were sustained. Rates of attacks treated with on-demand medication fell 83%, and moderate-to-severe attacks fell 77%. Compared with their own pre-treatment rates, 98%, 96%, and 65% of treated participants had attack reductions of at least 50%, 70%, and 90%, and 45% had no attacks during the whole 24 weeks. Quality-of-life scores improved significantly more than with placebo. The company reports no treatment-related serious adverse events or cardiovascular events.

Other presentations covered the rest of the program. Final results from the Phase 2 CHAPTER-1 open-label extension, presented by Michael E. Manning, M.D., showed a mean 92.4% reduction in attack rate from baseline over up to about 34 months, with a mean monthly rate of 0.12 compared with 2.18 at baseline. No treatment-related severe or serious adverse events were reported, and none led to discontinuation. John Anderson, M.D., presented Phase 3 RAPIDe-3 analyses of 88 participants with paired attacks, in which the 20 mg immediate-release capsule reached the “end of progression” point in a median 17.47 minutes versus more than 3.5 hours with placebo. Anne Lesage, Ph.D., presented population pharmacokinetic modeling suggesting that exposure from the extended-release tablet combined with one or two immediate-release capsules stayed below the highest levels tested in nonclinical and human studies, and an integrated analysis of more than 740 participants across 25 studies that found no evidence of QTc prolongation or increased cardiovascular events.

A U.S. closed claims analysis presented by Raffi Tachdjian, M.D., MPH, of 952 adolescents and adults with HAE found that, over a median 2.4 years, 20.3% had at least one HAE-related hospital stay and 25.4% had an emergency room visit. Median HAE-related medical and pharmacy costs per patient per year were $43,271 at baseline and $240,064 during follow-up. Pharvaris President Peng Lu, M.D., Ph.D., said the CHAPTER-3 reductions were in the range of those seen with injectable long-term prophylactic therapies, though the study didn’t compare the drugs directly.

All the clinical results come from company announcements and haven’t been peer reviewed, and the posters and slides are posted on the company’s investor site. The trial was placebo-controlled but modest in size, the 87% figure is post hoc, and the attack-free and responder percentages are within-group measures. The company says deucrictibant has orphan drug designation in the U.S., the European Union, and Switzerland.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free